HER2的可变剪接：表皮生长因子受体酪氨酸激酶抑制剂耐药性的新型介质 - Suppr

Suppr

超能文献

Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.

作者信息

Yochum Zachary A, Villaruz Liza C

机构信息

Division of Hematology-Oncology, Department of Medicine, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.

Medical Scientist Training Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.

出版信息

Transl Lung Cancer Res. 2020 Aug;9(4):1606-1612. doi: 10.21037/tlcr-20-618.

DOI:10.21037/tlcr-20-618

PMID:32953533

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7481647/

Abstract

摘要

相似文献

Alternative splicing of HER2: a novel mediator of EGFR TKI resistance.HER2的可变剪接：表皮生长因子受体酪氨酸激酶抑制剂耐药性的新型介质

Transl Lung Cancer Res. 2020 Aug;9(4):1606-1612. doi: 10.21037/tlcr-20-618.

IGFBP7 Drives Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibition in Lung Cancer.胰岛素样生长因子结合蛋白7驱动肺癌对表皮生长因子受体酪氨酸激酶抑制的耐药性。

Cancers (Basel). 2019 Jan 2;11(1):36. doi: 10.3390/cancers11010036.

Emergence of RET rearrangement co-existing with activated EGFR mutation in EGFR-mutated NSCLC patients who had progressed on first- or second-generation EGFR TKI.在第一代或第二代EGFR TKI治疗中出现进展的EGFR突变型NSCLC患者中，RET重排与激活的EGFR突变共存的情况。

Lung Cancer. 2015 Sep;89(3):357-9. doi: 10.1016/j.lungcan.2015.06.021. Epub 2015 Jun 29.

Triple Trouble: A Case of Multiple Resistance Mechanisms after First Generation EGFR-TKI in NSCLC.三重困境：1例非小细胞肺癌患者在第一代表皮生长因子受体酪氨酸激酶抑制剂治疗后出现多种耐药机制的病例

Case Rep Oncol. 2019 Aug 6;12(2):625-630. doi: 10.1159/000502214. eCollection 2019 May-Aug.

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.曲妥珠单抗联合紫杉醇治疗 EGFR-TKI 治疗进展后 HER2 过表达的 EGFR 突变型 NSCLC 患者。

Br J Cancer. 2018 Aug;119(5):558-564. doi: 10.1038/s41416-018-0194-7. Epub 2018 Jul 31.

Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells.双特异性酪氨酸激酶抑制剂 AEE788 对人表皮生长因子受体 2 的额外抑制对胶质细胞瘤细胞对特定 EGFR 抑制的耐药性的影响。

Int J Mol Med. 2010 Nov;26(5):713-21. doi: 10.3892/ijmm_00000518.

HER2 overexpression reverses the relative resistance of EGFR-mutant H1975 cell line to gefitinib.HER2过表达逆转了EGFR突变的H1975细胞系对吉非替尼的相对耐药性。

Oncol Lett. 2016 Dec;12(6):5363-5369. doi: 10.3892/ol.2016.5373. Epub 2016 Nov 9.

Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs.下一代测序揭示了 EGFR-TKI 获得性耐药的 EGFR 突变型非小细胞肺癌中的新型耐药机制和分子异质性。

Lung Cancer. 2017 Nov;113:106-114. doi: 10.1016/j.lungcan.2017.09.005. Epub 2017 Sep 12.

Response to HER2 Inhibition in a Patient With Brain Metastasis With EGFR TKI Acquired Resistance and an HER2 Amplification.一名具有EGFR TKI获得性耐药和HER2扩增的脑转移患者对HER2抑制的反应。

Front Oncol. 2018 May 22;8:176. doi: 10.3389/fonc.2018.00176. eCollection 2018.

TC-N19, a novel dual inhibitor of EGFR and cMET, efficiently overcomes EGFR-TKI resistance in non-small-cell lung cancer cells.TC-N19是一种新型的表皮生长因子受体（EGFR）和间质上皮转化因子（cMET）双重抑制剂，能有效克服非小细胞肺癌细胞中的EGFR酪氨酸激酶抑制剂（EGFR-TKI）耐药性。

Cell Death Dis. 2016 Jun 30;7(6):e2290. doi: 10.1038/cddis.2016.192.

引用本文的文献

Alternative Splicing in Tumorigenesis and Cancer Therapy.肿瘤发生与癌症治疗中的可变剪接

Biomolecules. 2025 May 29;15(6):789. doi: 10.3390/biom15060789.

Multi-omics approach to identifying isoform variants as therapeutic targets in cancer patients.用于识别异构体变体作为癌症患者治疗靶点的多组学方法。

Front Oncol. 2022 Nov 24;12:1051487. doi: 10.3389/fonc.2022.1051487. eCollection 2022.

本文引用的文献

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance Mutations.一线奥希替尼耐药突变的药物敏感性和等位基因特异性。

Cancer Res. 2020 May 15;80(10):2017-2030. doi: 10.1158/0008-5472.CAN-19-3819. Epub 2020 Mar 19.

Cancer statistics, 2020.癌症统计数据，2020 年。

CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.

Tumor Analyses Reveal Squamous Transformation and Off-Target Alterations As Early Resistance Mechanisms to First-line Osimertinib in -Mutant Lung Cancer.肿瘤分析揭示鳞状转化和脱靶改变是 - 突变肺癌一线奥希替尼耐药的早期机制。

Clin Cancer Res. 2020 Jun 1;26(11):2654-2663. doi: 10.1158/1078-0432.CCR-19-3563. Epub 2020 Jan 7.

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer.奥希替尼治疗 EGFR 突变型非小细胞肺癌的耐药机制。

Br J Cancer. 2019 Oct;121(9):725-737. doi: 10.1038/s41416-019-0573-8. Epub 2019 Sep 30.

Exon 16-Skipping HER2 as a Novel Mechanism of Osimertinib Resistance in EGFR L858R/T790M-Positive Non-Small Cell Lung Cancer.外显子 16 跳跃 HER2 作为 EGFR L858R/T790M 阳性非小细胞肺癌中奥希替尼耐药的新机制

J Thorac Oncol. 2020 Jan;15(1):50-61. doi: 10.1016/j.jtho.2019.09.006. Epub 2019 Sep 23.

Case Rep Oncol. 2019 Aug 6;12(2):625-630. doi: 10.1159/000502214. eCollection 2019 May-Aug.

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial.帕博利珠单抗对比化疗用于未经治疗、PD-L1 表达、局部晚期或转移性非小细胞肺癌（KEYNOTE-042）：一项随机、开放标签、对照、III 期临床试验。

Lancet. 2019 May 4;393(10183):1819-1830. doi: 10.1016/S0140-6736(18)32409-7. Epub 2019 Apr 4.

Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report.奥希替尼联合阿法替尼治疗 EGFR T790M 突变及对厄洛替尼耐药后出现多种 HER2 改变的肺腺癌一例报告

Thorac Cancer. 2018 Dec;9(12):1774-1777. doi: 10.1111/1759-7714.12889. Epub 2018 Oct 8.

Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.靶向 EMT 转录因子 TWIST1 克服 EGFR 突变型非小细胞肺癌对 EGFR 抑制剂的耐药性。

Oncogene. 2019 Jan;38(5):656-670. doi: 10.1038/s41388-018-0482-y. Epub 2018 Aug 31.

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC.阿替利珠单抗作为转移性非鳞状 NSCLC 一线治疗药物。

N Engl J Med. 2018 Jun 14;378(24):2288-2301. doi: 10.1056/NEJMoa1716948. Epub 2018 Jun 4.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验